CID-103
Monoclonal antibody
Evidence outlook
Mid-stage study registered, not yet recruiting
Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
Also in development:Multiple Myeloma · Phase 1
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT07017725 NCT07017725 · Immune Thrombocytopenia Registry: NCT07017725 | 1/2 | Safety and tolerability of CID-103 (10 months); Platelet response (12 weeks) 2026-06-01 | In progress: primary completion was expected 1 Jun 2026; results not posted | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Phase 1/2 (2)
What this study did
What this study did
Phase 1 (1)
What this study did
Competitive landscape
Other CD38 drugs
Daratumumab, Isatuximab, BCD-264, CT-P44, Felzartamab and 7 more. Compare all 13 CD38 drugs
This mechanism is crowded: 13 other tracked programmes target it, 11 of them ahead of this one.
This drug's own stage for Immune Thrombocytopenia: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| CID-103: this drug | Phase 2 | Monoclonal antibody | CD38 | not yet graded | No reviewed efficacy summary in this indication | |
| Fostamatinib (Tavalisse) | Approved | Small molecule | Spleen tyrosine kinase (Syk) | not yet graded | No reviewed efficacy summary in this indication | |
| Rilzabrutinib | Approved | Small molecule | BTK | Reliable signal | No reviewed efficacy summary in this indication | |
| Mezagitamab | Phase 3(overall) | Monoclonal antibody | CD38 | Weak signal(overall) | No reviewed efficacy summary in this indication |
Compare side by side
5 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow CID-103 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.